Enveric Biosciences, Inc. (ENVB) stock
ENVBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.44−0.07 (-4.95%)
Close on Nov 16, 2026Market cap $6.45MP/E –Yield –
Earnings
Enveric Biosciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 26, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
$0.57
-$10.81 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Enveric Biosciences's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 26, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 13, 2026after the close | – | – | $0.57 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 14, 2026during market hours | – | – | $0.76 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 15, 2026before the open | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 27, 2026during market hours | – | – | -$6.12 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 14, 2025during market hours | – | – | -$10.81 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 14, 2025before the open | – | – | -$0.97 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 14, 2025during market hours | – | – | $1.22 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 31, 2025before the open | – | – | -$4.83 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 14, 2024during market hours | – | – | -$0.24 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 12, 2024during market hours | – | – | $0.23 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 15, 2024after the close | – | – | $0.61 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 26, 2024before the open | – | – | $1.46 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 13, 2023during market hours | – | – | $1.30 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 14, 2023before the open | – | – | $3.04 | Release |
| Q1 FY2023ended Mar 31, 2023 | Apr 3, 2023during market hours | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Apr 3, 2023during market hours | – | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | Apr 1, 2022during market hours | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Apr 1, 2022during market hours | – | – | – | Release |
| Q1 FY2021ended Mar 31, 2021 | May 20, 2021during market hours | – | – | – | Filing |
| Q3 FY2018ended Sep 30, 2018 | Nov 15, 2018during market hours | – | – | – | Filing |
| Q2 FY2018ended Jun 30, 2018 | Aug 14, 2018before the open | – | – | – | Filing |
| Q1 FY2018ended Mar 31, 2018 | May 15, 2018before the open | – | – | – | Filing |
| Q3 FY2017ended Sep 30, 2017 | Nov 14, 2017during market hours | – | – | – | Filing |
| Q2 FY2017ended Jun 30, 2017 | Aug 18, 2017during market hours | – | – | – | Filing |
| Q1 FY2017ended Mar 31, 2017 | Apr 7, 2017during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Enveric Biosciences has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Enveric Biosciences puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Enveric Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- News
- News
- News
- Results
- Update
- Results
- News
- Update
- Update
- Results
- Results
See a number that looks wrong?